Clinical Trials Logo
  1. Home
  2. Cocaine-Related Disorders
  3. NCT00032916
  4. Details
NCT00032916 Clinical Trial

Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers - 1

Cocaine-Related Disorders Clinical Trial

Official title:
Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT00032916
Other study ID # NIDA-CPU-2359-02-1
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received April 5, 2002
Last updated January 10, 2017
Start date June 2001
Est. completion date December 2002

Study information
Verified date April 2004
Source National Institute on Drug Abuse (NIDA)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The purpose of this study is to conduct a drug interaction study with NS2359 and cocaine in cocaine experienced volunteers.

Description:

This is a single-center, double-blind, placebo-controlled, randomized, single dose, fixed order, dose escalating inpatient design that will study oral NS2359 in cocaine experienced volunteers.

Other known NCT identifiers
  • NCT00031330

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 24
Est. completion date December 2002
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

Male or Female, 18-45 yrs of age; females of child-bearing potential using appropriate method of birth control; be able to understand the procedure and agrees to participate via informed consent; must be cocaine dependent according to DSM-4 criteria; must be capable of providing written consent; must be able to comply with protocol requirement, CPU rules and regulations; must not be currently seeking treatment for cocaine abuse.

Exclusion Criteria:

Incapable of understanding the informed consent process; Additional criteria available during screening at the site.

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• NS2359

Locations
Country Name City State
United States Uniformed Services University of Health Science Bethesda Maryland

Sponsors (1)
Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Pharmacokinetic parameter comparison
Primary plasma concentration
See also
  Status Clinical Trial Phase
Completed NCT01526538 - Improving Learning-based Treatment of Cocaine Dependence With Medication Phase 2
Completed NCT00877435 - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial N/A
Completed NCT00430690 - Acoustic Startle Reduction In Cocaine Dependence
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Active, not recruiting NCT00094315 - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1 Phase 1
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT00218348 - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Phase 2
Completed NCT00158132 - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2 Phase 2
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00000294 - Effects of Carvedilol on Cocaine Use in Humans - 11 Phase 2
Completed NCT00015054 - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Phase 2
Completed NCT00000308 - Dextroamphetamine-Cocaine Behavioral Intervention - 5 Phase 2
Completed NCT00000314 - M-CPP and Fenfluramine in Cocaine Addicts - 3 Phase 2
Completed NCT00000277 - Mazindol for Cocaine Abuse - 2 Phase 2
Completed NCT00000188 - Selegiline in Treatment of Cocaine Dependence - 2 Phase 2
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Completed NCT00000280 - Glutaminergic Agents for Cocaine Abuse - 5 Phase 1
Completed NCT00000281 - Pharmacotherapy for Schizophrenic Drug Users - 6 Phase 2
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2
Terminated NCT00000276 - Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Phase 1